Islet Autoantibody Analysis: Radioimmunoassays

Area of Science:

• Immunology
• Endocrinology
• Diabetology

Background:

• Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells.
• Antibodies to islet autoantigens, including GADA, IA-2A, IA-2β, ZnT8A, and IAA, are key biomarkers for T1D.
• Radioimmunoassay (RIA) is established as the gold standard for measuring these T1D autoantibodies.

Purpose of the Study:

• To describe current radioimmunoassay (RIA) methods for measuring autoantibodies relevant to Type 1 diabetes (T1D).
• To highlight the utility of RIA in quantifying antibodies against major islet autoantigens.

Main Methods:

• Fluid phase assays utilizing radiolabeled ligands.
• Immunoprecipitation techniques for autoantibody quantification.
• Measurement of autoantibodies to GAD, IA-2, ZnT8, and insulin.

Main Results:

• RIA provides high specificity and sensitivity for detecting T1D autoantibodies.
• Testing for GADA, IA-2A, and IAA can identify over 85% of newly diagnosed or future T1D cases with 98% specificity.
• RIA methods accurately quantify antibodies to GAD, IA-2, ZnT8, and insulin.

Conclusions:

• Radioimmunoassay (RIA) remains a definitive method for measuring Type 1 diabetes (T1D) autoantibodies.
• These RIA assays are crucial for the accurate diagnosis and understanding of T1D pathogenesis.